Skip to main content
SRD Smart Compare
Antibiotic efficacy meta-analysis

© 2018 Bayer Animal Health, Leverkusen, Germany

Bayer, the Bayer Cross and Baytril are registered trademarks of Bayer. All other products are trademarks of their respective owners

» Language
  • English
  • Italiano
  • Español
  • 简体中文
  • 繁體中文
  • 한글
  • Tiếng Việt
Home
  • English
  • Italiano
  • Español
  • 简体中文
  • 繁體中文
  • 한글
  • Tiếng Việt

Are you getting the most out of your SRD treatment?

SRD Smart Compare uses independent scientific evidence to make easy and direct comparisons between injectable antibiotics. It has been designed to help you make fact-based decisions on swine respiratory disease treatments in order to improve animal health with less antibiotic treatments.

Are you getting the most out of your SRD treatment?

SRD Smart Compare uses independent scientific evidence to make easy and direct comparisons between injectable antibiotics. It has been designed to help you make fact-based decisions on swine respiratory disease treatments in order to improve animal health with less antibiotic treatments.

This website contains information on antibiotic molecules for veterinary use to treat swine respiratory disease (SRD) by injection. It is based on the publication O’Connor AM, Totton SC, Shane D. A systematic review and network meta-analysis of injectable antibiotic treatment options for naturally occurring swine respiratory disease. J Swine Health Prod. 2019;27(3):133-150. A calculator interface allows to conveniently compare any two of the analyzed antibiotic molecules based on the results of the global meta-analysis study (risk of treatment failure).

Due to legal considerations in different countries, the content of this site is only available for members of the veterinary profession. By clicking the link below, you agree that your profession and your knowledge allow you to access veterinary information.

Disclaimer

The information provided by this website including the results of the calculation do not constitute a recommendation by Elanco for the use of any specific product or active ingredient. The calculator is solely meant to assist you in reading and evaluating the network meta-analysis. No representation is made or warranty given, either expressly or tacitly, for the completeness or correctness of the information on this website and the results of the calculator. Any choice and application of product is at your own responsibility and risk.

Responsible Use of Antibiotics

All antibiotics should be prescribed and used responsibly. Considering comparative efficacy is one of the important factors when prescribing antibiotics, others include for example: use of sensitivity test results, label and leaflet recommendations on use and warnings, local circumstances and local antibiotic prescribing policies.

The research behind:
Creating transparency on antibiotic efficacy
Directly comparing antibiotics is a scientific challenge. Due to time and resource constraints, published studies are not available for all possible antibiotic comparisons. Systematic review followed by network meta-analysis enables the assessment of comparative efficacy between antibiotics even in case no head-to-head studies are available.

O’Connor AM, Totton SC, Shane D. A systematic review and network meta-analysis of injectable antibiotic treatment options for naturally occurring swine respiratory disease. J Swine Health Prod. 2019;27(3):133-150.

Click here to view the paper

  • Independent review and analysis of accessible studies
  • Scientifically validated methods modelling probability of treatment success and assessing risk of bias
  • 34 studies from 11 countries included in analysis (1266 records screened)
  • 10 antibiotic molecules evaluated in model

© 2020 Elanco or its affiliates.

Conditions of Use Privacy Statement Imprint
Principles

Principles

Principles

Reference

Restart

Restart

Reference

O’Connor AM, Totton SC, Shane D. A systematic review and network meta-analysis of injectable antibiotic treatment options for naturally occurring swine respiratory disease. J Swine Health Prod. 2019;27(3):133-150.

Click here to view the paper
What is the basis of the calculations?

O'Connor et al. used systematic review and meta-analysis to compare the efficacy of antibiotic treatments for SRD. The network of evidence contained 34 studies conducted in 11 different countries, representing 10 active ingredients. The output from the analysis provided information about the probability of treatment response and the treatment failure risk ratio comparing all possible treatments including both direct and indirect data. The SRD Smart Compare tool is built on the data published in tables 5 (page 147) & S5 (supplementary material 2) of the publication.

On which basis is the statement on superior efficacy between two antibiotics made?

The risk ratio (RR) between two antibiotics gives insights whether one antibiotic has a significantly higher risk of treatment failure than another and therefore shows lower efficacy in the meta-analysis. The upper right-hand section of the table below provides the risk ratio (RR) for treatment failure of the antibiotic in the row (nominator) compared to the antibiotic in the column (denominator) and the lower left-hand section displays the corresponding 95% confidence intervals (CI). If the CI interval for two selected antibiotics crosses 1, then there is no substantial evidence of difference in efficacy. For example, the RR between florfenicol (FLO; row = nominator) and marbofloxacin (MAR; column = denominator) is 2.55, but CI = 0.28 – 11.47, so there is no substantial evidence to say that one of them is more efficacious than the other as the CI crosses 1.

However, if the CI interval does not cross 1 and RR is different than 1, than there is substantial evidence of difference. Taking the example of amoxicillin (AMX; row = nominator) and enrofloxacin (ENF; column = denominator), RR = 10.15 and CI = 1.54 – 37.44, so one can state that there is substantial evidence of difference between the two antibiotics. The risk of treatment failure for AMX is 10.15 times higher than for ENF, meaning that AMX is less efficacious than ENF. To follow the idea, if RR is lower than 1 and CI does not cross 1, the antibiotic in the row is more effective than the antibiotic in the column. This is the case for example between enrofloxacin (ENF; row = nominator) and tildipirosin (TIL; column = denominator), where RR = 0.20 and CI = 0.04-0.53. This means that there is substantial evidence that ENF is more effective than TIL, because the risk of treatment failure for ENF is 0.20 times of TIL.

You can find the data in table 5 (page 147) in the publication.

How is the number of estimated treatment failures calculated?

Estimated treatment failures shown in SRD Smart Compare are calculated using the inverse of the mean probability of treatment response reported in the study. This is actually the mean probability of treatment failure, which is then multiplied with the SRD treatment numbers you entered as a baseline for analysis. E.g. for Amoxicillin, the mean probability of treatment response is 79%, which means a mean probability of treatment failure of 21%. If you entered that you treat 100 pigs for SRD, this would lead to a calculated estimated number of treatment failures of 21.

You can find the data in table S5 (supplementary material 2) in the publication.

Which treatment regimes have been used in the studies analysed in the meta-analysis?

Treatment regimes for antibiotic molecules reported in the model based on table 1 (page 135):

Antibiotic molecule Treatment regimes
Non-active control Saline, non-drug, sterile diluent, placebo
Amoxicillin 15 mg/kg, 2 doses 48 hours apart
Ceftiofur crystalline free acid (CFA) 5 mg ceftiofur equivalent/kg once
Ceftiofur hydrochloride or sodium (MD) 3-5 mg/kg SID q 3 days
Enrofloxacin 7.5 mg/kg once or 2.5-5 mg/kg SID q 3-5 days
Florfenicol 15 mg/kg, 2 doses 48 hours apart
Gamithromycin 6 mg/kg once
Marbofloxacin 8 mg/kg once or 2 mg/kg SID q 3 days
Oxytetracycline 9 mg/lb (4.1 mg/kg) once or 5-10 mg/kg once
Tildipirosin 4 mg/kg once
Tulathromycin 2.5 mg/kg once

Imprint

Elanco US

2500 Innovation Way

Greenfield, IN 46140 USA

Phone: 1-877-Elanco1 (1-877-352-6261)

Privacy Statement

This website (hereinafter the “Website“) is provided by Elanco US (hereinafter “us” or “we”). For further information regarding the provider of the Website, please refer to our imprint.

Information on other selected non-Website related data processing activities performed by us and all of our affiliates in Germany (e.g. when you give us a business card or we collect your data from publicly available sources) can be found in the privacy information for selected specific processing activities.

Handling of personal data

In the following we wish to provide you with information on how we handle your personal data when you use our Website. Unless otherwise indicated in the following chapters, the legal basis for the handling of your personal data results from the fact that such handling is required to make available the functionalities of the Website requested by you (Art. 6(1)(b) General Data Protection Regulation).

Using our Website
Accessing our Website

When you call up our Website, your browser will transfer certain information to our web server. This is done for technical reasons and required to make available to you the requested information. To facilitate your access to the Website, the following information are collected, briefly stored and used:

  • IP address
  • date and time of access
  • Time zone difference to Greenwich Mean Time (GMT)
  • Content of request (specific site)
  • Status of access/HTTP status code
  • Transferred volume of data
  • Website requesting access
  • Browser, language settings, version of browser software operating system and surface

Moreover, to protect our legitimate interests, we will store such information for a limited period of time in order to be able to initiate a tracking of personal data in the event of actual or attempted unauthorized access to our servers (Art. 6(1)(f) General Data Protection Regulation).

Setting of cookies
What are cookies?

This Website uses so-called “cookies”. Cookies are small text files that are stored in the memory of your terminal via your browser. They store certain information (e.g. your preferred language or site settings) which your browser may (depending on the lifespan of the cookie) retransmit to us upon your next visit to our Website.

What cookies do we use?

We differentiate between two categories of cookies: (1) functional cookies, without which the functionality of our Website would be reduced, and (2) optional cookies used for e.g. website analysis and marketing purposes. The following tables contain a detailed description of the optional cookies we use:

Optional Cookies

Name Purpose and Content Consent
Website analysis with Google

Website analysis with Google
Questi cookie assegnano un ID generato in modo casuale al dispositivo, consentendo di riconoscere il tuo dispositivo al tuo prossimo accesso. Per i dettagli sulle analisi dei siti web si rimanda al relativo paragrafo.

Lifespan: 6 months
Provider: Google Inc.
Personalization with Acquia

These cookies assign a randomly generated ID to your device, enabling us and our partners to recognize your device upon your next access. For details on the personalization service please see the respective chapter below.

Lifespan: 1 year
Provider: Acquia Inc.
Subject to your consent

We only use optional cookies if we have obtained your prior consent (Art. 6(1)(a) General Data Protection Regulation). Upon your first access to our Website, a banner will appear, asking you to give us your consent to the setting of optional cookies. If your consent is given, we will place a cookie on your computer and the banner will not appear again as long as the cookie is active. After expiration of the cookie’s lifespan, or if you actively delete the cookie, the banner will reappear upon your next visit to our Website and again ask for your consent.

How to prevent the setting of cookies

Of course you may use our Website without any cookies being set. In your browser, you can at any time configure or completely deactivate the use of cookies. This may, however, lead to a restriction of the functions or have adverse effects on the user-friendliness of our Website. You may at any time object to the setting of optional cookies by using the respective objection option indicated in the table above.

Website Analysis with Google

On our Website we use a web analysis service of Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States („Google“).

Google will analyze your use of our Website on our behalf. To this purpose, we use the cookies described in more detail in the above table. The information collected by Google in connection with your use of our Website (e.g. the referring URL, our webpages visited by you, your browser type, your language settings, your operating system, your screen resolution) will be transmitted to a server of Google in the US, where it will be stored and analyzed. The respective results will then be made available to us in anonymized form. Your usage data will not be connected to your full IP address during this process. We have activated on our Website the IP anonymizing function offered by Google, which will delete the last 8 bits (type IPv4) or the last 80 bits (type IPv6) of your IP address after each data transfer to Google. Moreover, Google is certified under the EU-US Privacy Shield, which ensures that an adequate level of data protection is maintained with respect to the processing of personal data by Google in the US.

You may withdraw your consent to the use of web analysis at any time, either by downloading and installing the provided Google Browser Plugin or by administrating your consents in the above table, in which case an opt-out cookie will be placed. Both options will prevent the application of web analysis only as long as you use the browser on which you installed the plugin and do not delete the opt-out Cookie.

Personalization with Acquia

On our Website we use a personalization service of Acquia lnc., 53 State Street, Boston MA 02109, United States („Acquia“).

Acquia will analyze your use of our Website on our behalf. To this purpose, we use the cookies described in more detail in the above table. The information collected by Acquia in connection with your use of our Website (e.g. the referring URL, our webpages visited by you, your browser type, your language settings, your operating system and further information depending on the implemented website events) will be transmitted to servers of Acquia in and outside the EU, where it will be stored and analyzed.

We and our partner Acquia will use this information to better tailor our content on this Website to you and your interests and to evaluate the efficiency of such personalization. When you visit another Elanco Website that also uses personalization and if you have consented to the use of cookies, customized content tailored to your interests can be presented to you based on the information collected on our Website.

Acquia is certified under the EU-US Privacy Shield and has concluded the EU standard contractual clauses for processors with us, which ensures that an adequate level of data protection is maintained with respect to the processing of personal data by Acquia outside the EU. You may withdraw your consent to personalization at any time, by administrating your consents in the above table, in which case an opt-out cookie will be placed. Please note that this will only prevent any use of personalization services as long as you do not delete the opt-out Cookie.

Information on side effects and quality complaints

This Website is not intended or designed for communications regarding side effects, lack of therapeutic effect, medication errors, grey market products/counterfeit medicine, incorrect or off-label use, quality complaints

and/or other issues regarding the safeness or quality of Elanco products. If you wish to report side effects or make a quality complaint, please contact your health care professional (e.g. physician or pharmacist), your local health authority, or use our Website for the report of undesirable side effects.

If you nevertheless report to us undesirable side effects or other issues regarding the safeness or quality of Elanco products, we will be legally bound to deal with your communication and may have to contact you for clarification purposes. Subsequently, we may have to notify the competent health authorities of the issues reported by you. In this context, your information will be forwarded in pseudonymized form, i.e. no information by which you may be directly identified will be passed on. We may also have to forward these pseudonymized notifications to our group companies and cooperation partners, to the extent these are likewise obliged to notify their respectively competent health authorities.

Transfer of personal data for commissioned processing

For the processing of your personal data we will to some extent use specialized service contractors. Such service contractors are carefully selected and regularly monitored by us. Based on respective data processor agreements, they will only process personal data upon our instruction and strictly in accordance with our directives.

Processing of personal data outside the EU / the EEA

Your personal data will in part also be processed in countries outside the European Union (“EU”) or the European Economic Area (“EEA”), which may have a lower data protection level than European countries. In such cases, we will ensure that a sufficient level of protection is provided for your personal data, e.g. by concluding specific agreements with our contractual partners (copy available on request), or we will ask for your explicit consent to such processing.

Transfer of personal data in case of a corporate restructure

In the event of a corporate restructure, such as a merger, sale or other transfer of all or part of our business or assets, we may transfer the information collected in connection with your use of this website to the acquirer to the extent permitted by law in order to ensure the continuous use of the offered services.

Information regarding your rights

The following rights are in general available to you according to applicable data privacy laws:

  • Right of information about your personal data stored by us;
  • Right to request the correction, deletion or restricted processing of your personal data;
  • Right to object to a processing for reasons of our own legitimate interest, public interest, or profiling , unless we are able to proof that compelling, warranted reasons superseding your interests, rights and freedom exist, or that such processing is done for purposes of the assertion, exercise or defense of legal claims;
  • Right to data portability;
  • Right to file a complaint with a data protection authority;
  • You may at any time with future effect withdraw your consent to the processing of your personal data. For further information please refer to the chapters above describing the processing of personal data based on your consent.

If you wish to exercise your rights, please address your request to the contact indicated below. (-> Contact).

Contact

For any questions  you may have with respect to data privacy, please submit a Data Subject Rights Request to

https://submit-irm.trustarc.com/services/validation/b175e13f-4236-4186-9a33-b7a446bc3692

or contact our company data protection officer at the following address:

[email protected]

 

Amendment of Privacy Statement

We may update our Privacy Statement from time to time. Updates of our Privacy Statement will be published on our Website. Any amendments become effective upon publication on our Website. We therefore recommend that you regularly visit the site to keep yourself informed on possible updates.

Last updated: 03.08.2020.

 

https://www.elancostatements.com/en/terms-of-use/elanco-com

 


© 2018 Bayer Animal Health, Leverkusen, Germany

Bayer, the Bayer Cross and Baytril are registered trademarks of Bayer. All other products are trademarks of their respective owners

Conditions of Use Privacy Statement Imprint